Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory and That Expresses E-selectin Ligand on the Cell

• Status: Not yet recruiting
• Trial end date: 2025-11-03

Summary

This phase I trial tests the safety, side effects, and best dose of uproleselan in combination with fludarabine and cytarabine in treating patients with acute myeloid leukemia, myelodysplastic syndrome, or mixed phenotype acute leukemia that has come back (relapsed) or does not respond to treatment (refractory) and the expresses E-selectin ligand on the cell membrane. Uproleselan binds to E-selectin expressed on endothelial cells and prevents their interaction with selectin-E ligand-expressing cancer cells. This may prevent tumor cell activation, migration, and spreading to other places in the body (metastasis). Chemotherapy drugs, such as fludarabine and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving uproleselan in combination with fludarabine and cytarabine may cause cancer to stop growing or to shrink for a period of time.

• Phase: Phase 1

Details

• Lead Sponsor: Children's Oncology Group
• Collaborators: National Cancer Institute (NCI); The Leukemia and Lymphoma Society
• Treatments: Cytarabine; Fludarabine; Fludarabine phosphate; Vidarabine